Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
5(56%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_4
1
11%
Ph phase_2
3
33%
Ph not_applicable
2
22%
Ph phase_1
2
22%

Phase Distribution

2

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
2(25.0%)
Phase 2Efficacy & side effects
3(37.5%)
Phase 4Post-market surveillance
1(12.5%)
N/ANon-phased studies
2(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

9

all time

Status Distribution
Active(5)
Completed(3)
Other(1)

Detailed Status

Recruiting5
Completed3
unknown1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
5
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (25.0%)
Phase 23 (37.5%)
Phase 41 (12.5%)
N/A2 (25.0%)

Trials by Status

completed333%
unknown111%
recruiting556%

Recent Activity

5 active trials
Showing 5 of 9
recruitingphase_1

SIRT With Tremelimumab and Durvalumab for Resectable HCC

NCT05701488
recruitingnot_applicable

SIRT Versus cTACE for Unresectable HCC (CHANCE2506)

NCT06909708
recruitingphase_2

Y-90 SIRT for Unresectable HCC Larger Than 7cm

NCT06707233
completedphase_2

Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis

NCT02936388
recruiting

Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors (SIRtain Registry)

NCT05967143
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT05701488Phase 1

SIRT With Tremelimumab and Durvalumab for Resectable HCC

Recruiting
NCT06909708Not Applicable

SIRT Versus cTACE for Unresectable HCC (CHANCE2506)

Recruiting
NCT06707233Phase 2

Y-90 SIRT for Unresectable HCC Larger Than 7cm

Recruiting
NCT02936388Phase 2

Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis

Completed
NCT05967143

Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors (SIRtain Registry)

Recruiting
NCT05994859Not Applicable

SIRT for Potentially Resectable HCC

Recruiting
NCT01798147Phase 2

Selective Internal Radiotherapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Cholangiocellular Carcinoma (CCC).

Unknown
NCT01798160Phase 4

Selective Internal Radiation Therapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Hepatocellular Carcinoma (HCC).

Completed
NCT00604409Phase 1

Study of Capecitabine in Combination With SIR-Spheres in Patients With Advanced Cancer

Completed

All 9 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
9